MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats

Brain Research

Volumn 736, Issue 1-2, 1996, Pages 202-205

  Marin, Concepció ^a,b   Papa, Stella ^a   Engber, Thomas M ^c   Bonastre, Mercè ^b   Tolosa, Eduardo ^b   Chase, T N ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CEPHALON INC   (United States)

Author keywords

6 hydroxydopamine; levodopa; MK801; motor fluctuation; rotation

Indexed keywords

DIZOCILPINE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

EID: 0030583640     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00693-2     Document Type: Article

References (15)

1. [1] Albin, R.L., Makowiec, Z.R., Hollingsworth, L.S., Dure, L.S. IV, Penny, J.B. and Young, A.B., Excitatory aminoacid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study, Neuroscience, 46 (1992) 35-48.
2. [2] Beal, M.F., Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol., 31 (1992) 119-130.
3. [3] Chase, T.N., Engber, T.M. and Mouradian, M.M., Striatal dopaminoceptive system changes and motor response complications in L-DOPA treated patients with advanced Parkinson's disease. Adv. Neurol., 60 (1993) 181-185.
4. [4] Chase, T.N., Engber, T.M. and Mouradian, M.M., Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease, Neurology, 44 (1994) (Suppl. 6), S15.
5. [5] Engber, T.M., Susel, Z., Juncos, J.L. and Chase, T.N., Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists, Eur. J. Pharmacol., 168 (1989) 291-298.
6. [6] Engber, T.M., Papa, S.M., Boldry, R.C. and Chase, T.N., Reversal by NMDA receptor blockade of the motor response alterations induced by chronic levodopa, NeuroReport, 5 (1994) 2586-2588.
7. [7] Klockgether, T. and Turski, L., Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease, Trends Neurosci., 12 (1989) 285-286.
8. [8] Marsden, C.D. and Parkes, J.D., Success and problems of long-term levodopa therapy in Parkinson's disease, Lancet, 1 (1977) 345-349.
9. [9] Meldrum, B., Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters, Clin. Sci., 68 (1985) 113.
10. [10] Papa, S.M., Engber, T.M. and Chase, T.N., Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration, Brain Res., 662 (1994) 69-74.
11. [11] Paxinos, G. and Watson, C., The Rat Bain in Stereotaxic Coordinates, Academic Press, New York, 1982.
12. [12] Starr, M., Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease, Synapse, 19 (1995) 264-293.
13. [13] St.-Pierre, J.A. and Bédard. P.J., Systemic administration of the NMDA receptor antagonist MK801 potentiates circling induced by intrastriatal microinjection of dopamine, Eur. J. Pharmacol., 272 (1995) 123-129.
14. [14] Standaert, D.G., Testa, C.M., Young, A.B. and Penney, J.B. Jr., Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat, J. Comp. Neurol., 343 (1994) 1-16.
15. [15] Wong, E.H.F., Kemp, J.A., Priestley, T., Knight, A.R., Woodruft, G.N. and Iversen, L.I., The anticonvulsant MK801 is a potent N-methyl-D-aspartate antagonist, Proc. Natl. Acad. Sci. USA, 83 (1986) 7104-7108.